Periodic Reporting for period 2 - FLUIDITY (Fighting Large-Scale Untreated Infectious Diseases with Innovative Treatments)
Reporting period: 2024-01-01 to 2024-12-31
The COVID-19 pandemic highlighted the unmet medical need for new antivirals that can help tackle existing and emerging viral infections. Funded by the European Innovation Council, the FLUIDITY project proposed to develop an innovative oral small molecule that limit internalisation and intracellular trafficking of viruses. The underlying concept is based on interfering with host membrane fluidity, which is beneficial as it has a broad-spectrum effect against multiple viruses. The molecule has also demonstrated an immunomodulatory effect, avoiding the immune system to react excessively after infection. As human safety is validated, the project was to perform a human proof of concept.
Work on Fluidity is now stopped. The API batch for the clinical trial is available, the clinical trial design is defined, first contacts with potential partners have begun.
Next main part of the project was to run the clinical trial and generate the first results in humans. Unfortunately, due to lack of funding, the project is discontinued
Next main part of the project was to run the clinical trial and generate the first results in humans. Unfortunately, due to lack of funding, the project is discontinued
Results of the clinical trial are not available yet as clinical trial is not completed